MX2018011629A - Complejos radiofarmaceuticos. - Google Patents
Complejos radiofarmaceuticos.Info
- Publication number
- MX2018011629A MX2018011629A MX2018011629A MX2018011629A MX2018011629A MX 2018011629 A MX2018011629 A MX 2018011629A MX 2018011629 A MX2018011629 A MX 2018011629A MX 2018011629 A MX2018011629 A MX 2018011629A MX 2018011629 A MX2018011629 A MX 2018011629A
- Authority
- MX
- Mexico
- Prior art keywords
- targeting
- tissue
- complex
- chelator
- thorium
- Prior art date
Links
- 229940121896 radiopharmaceutical Drugs 0.000 title 1
- 239000012217 radiopharmaceutical Substances 0.000 title 1
- 230000002799 radiopharmaceutical effect Effects 0.000 title 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 abstract 3
- 229910052776 Thorium Inorganic materials 0.000 abstract 3
- 239000002738 chelating agent Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical compound ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 abstract 2
- 230000008878 coupling Effects 0.000 abstract 2
- 238000010168 coupling process Methods 0.000 abstract 2
- 238000005859 coupling reaction Methods 0.000 abstract 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000002843 carboxylic acid group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 230000002390 hyperplastic effect Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención proporciona un método para la formación de un complejo de torio dirigido a tejido, que comprende; a) formar un quelador octadentado que comprende cuatro restos de hidroxipiridinona (HOPO), sustituidos en la posición N con un grupo metilo y un resto de acoplamiento que termina en un grupo de ácido carboxílico; b) acoplar dicho quelador octadentado con al menos un resto dirigido a tejido que apunta a HER2; y c) poner en contacto dicho quelador dirigido a tejido con una solución acuosa que comprende un ion de al menos un isótopo de torio emisor alfa. También se proporcionan un método de tratamiento de una enfermedad neoplásica o hiperplásica que comprende la administración de tal complejo de torio dirigido a tejido, así como el complejo y las correspondientes formulaciones farmacéuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16162123 | 2016-03-24 | ||
| PCT/EP2017/056503 WO2017162555A1 (en) | 2016-03-24 | 2017-03-20 | Radio-pharmaceutical complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018011629A true MX2018011629A (es) | 2019-03-14 |
Family
ID=55745553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011629A MX2018011629A (es) | 2016-03-24 | 2017-03-20 | Complejos radiofarmaceuticos. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11260136B2 (es) |
| EP (1) | EP3432936A1 (es) |
| JP (2) | JP2019513699A (es) |
| CN (1) | CN108778347A (es) |
| AR (1) | AR107957A1 (es) |
| AU (1) | AU2017239018A1 (es) |
| BR (1) | BR112018069485A2 (es) |
| CA (1) | CA3018607A1 (es) |
| CL (1) | CL2018002695A1 (es) |
| CO (1) | CO2018010024A2 (es) |
| IL (1) | IL261329B (es) |
| JO (1) | JOP20170072B1 (es) |
| MX (1) | MX2018011629A (es) |
| PE (1) | PE20190168A1 (es) |
| SG (2) | SG11201806548UA (es) |
| TW (1) | TWI757273B (es) |
| UA (1) | UA125749C2 (es) |
| UY (1) | UY37167A (es) |
| WO (1) | WO2017162555A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018011629A (es) * | 2016-03-24 | 2019-03-14 | Bayer Pharma AG | Complejos radiofarmaceuticos. |
| EP3843743A1 (en) | 2018-08-28 | 2021-07-07 | Bayer AS | Combination of pi3k-inhibitors and targeted thorium conjugates |
| CA3130747A1 (en) | 2019-02-21 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4880615A (en) | 1988-11-25 | 1989-11-14 | Merck & Co., Inc. | Stabilized radiopharmaceutical compositions |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5624901A (en) | 1994-04-15 | 1997-04-29 | The Regents Of The University Of California | 3-hydroxy-2(1H)-pyridinone chelating agents |
| NO312708B1 (no) | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
| NO313180B1 (no) | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| US7794691B2 (en) * | 2004-06-25 | 2010-09-14 | The European Community, Represented By The European Commission | Radionuclides for medical use |
| CA2596133C (en) * | 2005-02-23 | 2016-11-15 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
| CA2602122A1 (en) * | 2005-04-01 | 2006-10-05 | Medvet Science Pty. Ltd. | A method of diagnosis and treatment and agents useful for same |
| WO2008019290A2 (en) * | 2006-08-04 | 2008-02-14 | Astrazeneca Ab | Human antibodies to erbb 2 |
| CA2660800C (en) | 2006-08-15 | 2016-03-01 | The Regents Of The University Of California | Luminescent macrocyclic lanthanide complexes |
| CA2777242A1 (en) * | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201208309D0 (en) * | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
| MA41176A (fr) * | 2014-12-17 | 2017-10-24 | Bayer As | Complexes radio-pharmaceutiques |
| MX2018011629A (es) * | 2016-03-24 | 2019-03-14 | Bayer Pharma AG | Complejos radiofarmaceuticos. |
-
2017
- 2017-03-20 MX MX2018011629A patent/MX2018011629A/es unknown
- 2017-03-20 PE PE2018001861A patent/PE20190168A1/es unknown
- 2017-03-20 SG SG11201806548UA patent/SG11201806548UA/en unknown
- 2017-03-20 SG SG10202009424TA patent/SG10202009424TA/en unknown
- 2017-03-20 CA CA3018607A patent/CA3018607A1/en active Pending
- 2017-03-20 BR BR112018069485A patent/BR112018069485A2/pt not_active IP Right Cessation
- 2017-03-20 CN CN201780017966.8A patent/CN108778347A/zh active Pending
- 2017-03-20 WO PCT/EP2017/056503 patent/WO2017162555A1/en not_active Ceased
- 2017-03-20 US US16/087,040 patent/US11260136B2/en active Active
- 2017-03-20 AU AU2017239018A patent/AU2017239018A1/en not_active Abandoned
- 2017-03-20 JP JP2018547324A patent/JP2019513699A/ja active Pending
- 2017-03-20 EP EP17710976.6A patent/EP3432936A1/en not_active Withdrawn
- 2017-03-20 UA UAA201810278A patent/UA125749C2/uk unknown
- 2017-03-21 TW TW106109303A patent/TWI757273B/zh not_active IP Right Cessation
- 2017-03-22 JO JOP/2017/0072A patent/JOP20170072B1/ar active
- 2017-03-23 AR ARP170100720A patent/AR107957A1/es not_active Application Discontinuation
- 2017-03-23 UY UY0001037167A patent/UY37167A/es not_active Application Discontinuation
-
2018
- 2018-08-22 IL IL261329A patent/IL261329B/en active IP Right Grant
- 2018-09-24 CO CONC2018/0010024A patent/CO2018010024A2/es unknown
- 2018-09-24 CL CL2018002695A patent/CL2018002695A1/es unknown
-
2022
- 2022-01-21 US US17/581,808 patent/US20220143229A1/en not_active Abandoned
- 2022-08-30 JP JP2022136797A patent/JP2022173214A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3018607A1 (en) | 2017-09-28 |
| IL261329A (en) | 2018-10-31 |
| PE20190168A1 (es) | 2019-02-01 |
| UA125749C2 (uk) | 2022-06-01 |
| SG10202009424TA (en) | 2020-11-27 |
| TW201736389A (zh) | 2017-10-16 |
| CO2018010024A2 (es) | 2018-10-22 |
| US20190091354A1 (en) | 2019-03-28 |
| US20220143229A1 (en) | 2022-05-12 |
| JOP20170072B1 (ar) | 2022-03-14 |
| TWI757273B (zh) | 2022-03-11 |
| CL2018002695A1 (es) | 2019-01-18 |
| SG11201806548UA (en) | 2018-08-30 |
| JP2022173214A (ja) | 2022-11-18 |
| IL261329B (en) | 2021-04-29 |
| AU2017239018A1 (en) | 2018-08-16 |
| BR112018069485A2 (pt) | 2019-07-30 |
| WO2017162555A1 (en) | 2017-09-28 |
| US11260136B2 (en) | 2022-03-01 |
| JP2019513699A (ja) | 2019-05-30 |
| UY37167A (es) | 2017-10-31 |
| AR107957A1 (es) | 2018-07-04 |
| CN108778347A (zh) | 2018-11-09 |
| EP3432936A1 (en) | 2019-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502605A1 (en) | Radio-pharmaceutical complexes | |
| PH12017501125A1 (en) | Radio-pharmaceutical complexes | |
| CL2018002727A1 (es) | Medicina obtenida mediante la combinación de agonista fxr y arb | |
| CY1120362T1 (el) | Συμπλοκα εκπομπης στοχευσης αλφα-σωματιδιων που περιλαμβανουν ραδιονουκλιδιο θοριου και προσδεμα που περιεχει υδροξυπυριδινονη | |
| AR102105A1 (es) | Conjugado radiofarmacéutico | |
| EP4374924A3 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| NZ739770A (en) | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer | |
| JOP20170072B1 (ar) | معقدات صيدلية مشعة | |
| SG11201910113PA (en) | Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate | |
| Song | Overseas-Vertical City Project based on Trasit-Oriented Development_Osaka Abeno Harukas | |
| TH1701003363A (th) | สารเชิงซ้อนเภสัชรังสี | |
| TH147184A (th) | ส่วนผสมโพวิโดน-ไอโอดีนที่เสถียรภาพ |